What Do Strides Pharma Q2 Results Indicate About Its Business Recovery?
About Strides Pharma
Strides Pharma Science Limited, a global pharmaceutical company headquartered in Bengaluru, specializes in branded and generic formulations across regulated markets. The company reported another solid quarter in Q2FY26, supported by improved operational efficiency and sustained demand momentum in regulated markets.
Quarterly financial highlights
| Particulars | Q2FY26 | Q2FY25 |
|---|---|---|
| Net Profit | ₹127 Cr | ₹71.8 Cr |
| Revenue | ₹1,220 Cr | ₹1,166 Cr |
| EBITDA | ₹231 Cr | ₹184 Cr |
| EBITDA Margin | 18.96% | 15.81% |
Commentary: Strides Pharma showcased strong YoY improvement led by better US generics pricing, strong growth in institutional business, and expanding portfolio across emerging markets. Margins improved due to scale leverage and controlled expenses.
Peer comparison
| Company | Revenue (₹ Cr) | Net Profit (₹ Cr) | EBITDA Margin (%) |
|---|---|---|---|
| Strides Pharma | 1,220 | 127 | 18.96 |
| Granules India | 1,340 | 158 | 20.5 |
| Alkem Labs | 2,780 | 280 | 21.8 |
For timely breakout trades and positional setups aligned with pharma momentum, explore our Nifty Tip and BankNifty Tip insights.
SWOT analysis
| Strengths | Weaknesses |
|---|---|
|
|
| Opportunities | Threats |
|
|
Stay tuned to our regular Nifty Option Tip and BankNifty Tip updates for upcoming pharma sector plays.
Investor takeaway
Strides Pharma’s solid execution and margin recovery confirm its turnaround momentum. Rising institutional orders, improving capacity utilization, and the pipeline of US-approved generics strengthen growth visibility.
Investment View: Long-term — positive with scope for rerating; medium-term — maintain hold with target visibility; short-term — accumulation possible around ₹760–₹780 levels with strict risk management.
Related queries on pharma stocks
- What Is Driving Margin Recovery in Indian Pharma Companies?
- How Do US Generic Approvals Impact Strides Pharma’s Growth?
- Why Are Contract Manufacturing Orders Rising Post-FY25?
Read more actionable updates at Indian-Share-Tips.com, which is a SEBI Registered Advisory Services.
SEBI Disclaimer: The information provided in this post is for informational purposes only and should not be construed as investment advice. Readers must perform their own due diligence and consult a registered investment advisor before making any investment decisions.
